Kensey Nash's smaller puncture closure device gains CE-Mark:
This article was originally published in Clinica
Kensey Nash has CE-marked a smaller version of its Angio-Seal puncture closure device. The new 6F device will allow the company to address the largest segment of the estimated $1 billion puncture closure market following cardiovascular catheterisation procedures. Approximately 70% of the 6.5 million cardiovascular procedures performed each year are carried out through a 6F or smaller puncture in the femoral artery, said the Exton Pennsylvania-based company.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.